2019
Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection
Ma R, Jung TH, Peduzzi PN, Brown ST, Kyriakides TC. Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2019, 18: 2325958219849101. PMID: 31272313, PMCID: PMC6748500, DOI: 10.1177/2325958219849101.Peer-Reviewed Original ResearchConceptsDrug changesCox proportional hazards regression modelKaplan-Meier survival techniqueMultidrug-resistant HIV infectionProportional hazards regression modelsAdvanced-stage AIDSDrug regimen changesSurvival of patientsHazards regression modelsAntiretroviral clinical trialsClinical biomarker dataCause mortalityMedication changesARV regimenHIV infectionImproved survivalRegimen changeClinical outcomesNonclinical reasonsClinical trialsBiomarker changesTreatment historyMultidrug resistanceTherapy strategiesPatients
2017
2432
Huang Y, Brown S, Ma S, Kyriakides T. 2432. Journal Of Clinical And Translational Science 2017, 1: 37-37. PMCID: PMC6799711, DOI: 10.1017/cts.2017.137.Peer-Reviewed Original ResearchAdvanced HIV diseaseARV medicationsHIV diseaseVirtual phenotypeSubsequent managementARV treatment strategiesEffects of ARVHIV treatment trialsIndividual ARV drugsCD4 cell countAnti-retroviral drugsCurrent clinical practiceOpen labelSpecific ARVsStandard armARV regimenIntensive armViral loadTherapeutic optionsVital statusARV drugsTreatment trialsARV treatmentTreatment strategiesTrial randomization
2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials